Literature DB >> 23598716

Implementation of routine screening for Lynch syndrome in university and safety-net health system settings: successes and challenges.

Evelyn Marquez1, Zhuo Geng, Sarah Pass, Pia Summerour, Linda Robinson, Venetia Sarode, Samir Gupta.   

Abstract

PURPOSE: Routine screening for evidence of DNA mismatch repair abnormalities can identify colorectal cancer patients with Lynch syndrome, but impact in usual care settings requires study. After implementing routine screening at our university and safety-net health systems as usual practice, our aims were to determine outcomes, including screening process quality.
METHODS: We conducted a retrospective cohort study from 1 May 2010 to 1 May 2011. Screening included reflexive immunohistochemistry to evaluate DNA mismatch repair protein expression for patients with colorectal cancer aged ≤70 years, with a cancer genetics team following up results. Screening outcomes, as well as challenges to a high-quality screening process were evaluated.
RESULTS: We included 129 patients (mean age 56 years, 36% female); 100 had immunohistochemistry screening completed. Twelve patients had abnormal immunohistochemistry: four with definite Lynch syndrome, four with probable Lynch syndrome, and three without Lynch syndrome; one patient had an incomplete work-up. Lynch syndrome was confirmed for 6/13 asymptomatic relatives tested. Screening process quality was optimal for 77.5% of patients. Barriers to optimal quality screening included ensuring reflexive immunohistochemistry completion, complete follow-up of abnormal immunohistochemistry, and timely incorporation of results into clinical decision making.
CONCLUSION: Usual care implementation of routine screening for Lynch syndrome can result in significant rates of detection, even in a largely safety-net setting. To optimize implementation, challenges to high-quality Lynch syndrome screening, such as ensuring reflexive screening completion and clinically indicated genetic testing and follow-up for abnormal screens, must be identified and addressed.

Entities:  

Mesh:

Year:  2013        PMID: 23598716      PMCID: PMC5215584          DOI: 10.1038/gim.2013.45

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  24 in total

1.  Multilevel research and the challenges of implementing genomic medicine.

Authors:  Muin J Khoury; Ralph J Coates; Mary L Fennell; Russell E Glasgow; Maren T Scheuner; Sheri D Schully; Marc S Williams; Steven B Clauser
Journal:  J Natl Cancer Inst Monogr       Date:  2012-05

Review 2.  Toward improving the quality of cancer care: addressing the interfaces of primary and oncology-related subspecialty care.

Authors:  Stephen Hunt Taplin; Anne Brown Rodgers
Journal:  J Natl Cancer Inst Monogr       Date:  2010

3.  Multilevel factors affecting quality: examples from the cancer care continuum.

Authors:  Jane Zapka; Stephen H Taplin; Patricia Ganz; Eva Grunfeld; Katherine Sterba
Journal:  J Natl Cancer Inst Monogr       Date:  2012-05

4.  Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria.

Authors:  Matthew F Kalady; Ellen McGannon; Jon D Vogel; Elena Manilich; Victor W Fazio; James M Church
Journal:  Ann Surg       Date:  2010-09       Impact factor: 12.969

5.  Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer.

Authors:  C Richard Boland; Moshe Shike
Journal:  Gastroenterology       Date:  2010-04-21       Impact factor: 22.682

6.  Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results.

Authors:  Laura C Beamer; Marcia L Grant; Carin R Espenschied; Kathleen R Blazer; Heather L Hampel; Jeffrey N Weitzel; Deborah J MacDonald
Journal:  J Clin Oncol       Date:  2012-02-21       Impact factor: 44.544

7.  Microsatellite instability among individuals of Hispanic origin with colorectal cancer.

Authors:  Samir Gupta; Raheela Ashfaq; Payal Kapur; Bianca B Afonso; Thuy-Phuong T Nguyen; Faryal Ansari; C Richard Boland; Ajay Goel; Don C Rockey
Journal:  Cancer       Date:  2010-11-01       Impact factor: 6.860

8.  Lynch syndrome screening implementation: business analysis by a healthcare system.

Authors:  James M Gudgeon; Janet L Williams; Randall W Burt; Wade S Samowitz; Gregory L Snow; Marc S Williams
Journal:  Am J Manag Care       Date:  2011-08-01       Impact factor: 2.229

9.  Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting.

Authors:  Cecelia A Bellcross; Sara R Bedrosian; Elvan Daniels; Debra Duquette; Heather Hampel; Kory Jasperson; Djenaba A Joseph; Celia Kaye; Ira Lubin; Laurence J Meyer; Michele Reyes; Maren T Scheuner; Sheri D Schully; Leigha Senter; Sherri L Stewart; Jeanette St Pierre; Judith Westman; Paul Wise; Vincent W Yang; Muin J Khoury
Journal:  Genet Med       Date:  2011-10-27       Impact factor: 8.822

10.  The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer.

Authors:  Mercy Mvundura; Scott D Grosse; Heather Hampel; Glenn E Palomaki
Journal:  Genet Med       Date:  2010-02       Impact factor: 8.822

View more
  15 in total

1.  Screening for Lynch syndrome: it is time to shift the focus.

Authors:  Trilokesh D Kidambi; Jonathan P Terdiman
Journal:  Dig Dis Sci       Date:  2015-01-07       Impact factor: 3.199

2.  Universal tumor screening for Lynch syndrome: perspectives of Canadian pathologists and genetic counselors.

Authors:  Elizabeth Dicks; Daryl Pullman; Ken Kao; Andrée MacMillan; Charlene Simmonds; Holly Etchegary
Journal:  J Community Genet       Date:  2018-11-21

3.  A single institution experience in compliance with universal screening for Lynch syndrome in colorectal cancer.

Authors:  Amy L Hill; Kirandeep K Sumra; Marcia M Russell; James Yoo; Clifford Y Ko; Steven Hart; Zev Wainberg; J Randolph Hecht; Anne Y Lin
Journal:  J Gastrointest Surg       Date:  2014-12-13       Impact factor: 3.452

4.  Clinical decision support for whole genome sequence information leveraging a service-oriented architecture: a prototype.

Authors:  Brandon M Welch; Salvador Rodriguez-Loya; Karen Eilbeck; Kensaku Kawamoto
Journal:  AMIA Annu Symp Proc       Date:  2014-11-14

5.  When guidelines face reality - Lynch syndrome screening in the setting of public health system in a developing country.

Authors:  Vanessa Nascimento Kozak; Enilze Maria de Souza Fonseca Ribeiro; Milena Massumi Kozonoe; Sergio Ossamu Ioshii; Jose Claudio Casali da Rocha
Journal:  J Community Genet       Date:  2021-10-08

6.  Successful implementation of Lynch syndrome screening in a safety net institution.

Authors:  Trilokesh D Kidambi; Robin Lee; Jonathan P Terdiman; Lukejohn Day
Journal:  J Community Genet       Date:  2016-07-02

7.  Comparison of universal screening in major lynch-associated tumors: a systematic review of literature.

Authors:  George Kunnackal John; Vipin Das Villgran; Christine Caufield-Noll; Francis M Giardiello
Journal:  Fam Cancer       Date:  2021-01-11       Impact factor: 2.375

8.  Racial and Ethnic Disparities in Germline Genetic Testing of Patients With Young-Onset Colorectal Cancer.

Authors:  Pooja Dharwadkar; Garrett Greenan; Elena M Stoffel; Ezra Burstein; Sara Pirzadeh-Miller; Sayoni Lahiri; Caitlin Mauer; Amit G Singal; Caitlin C Murphy
Journal:  Clin Gastroenterol Hepatol       Date:  2020-12-24       Impact factor: 11.382

9.  When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives.

Authors:  Scott D Grosse
Journal:  Healthcare (Basel)       Date:  2015-09-24

10.  Worldwide variation in lynch syndrome screening: case for universal screening in low colorectal cancer prevalence areas.

Authors:  George Kunnackal John; Vipin Das Villgran; Christine Caufield-Noll; Francis Giardiello
Journal:  Fam Cancer       Date:  2020-09-11       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.